Explosive growth is attributed to the BCR::ABL1 gene 3–14 years before diagnosis of chronic myeloid leukaemia, highlighting the oncogenic potency of gene fusion and the slow and sequential trajectories of most other cancers. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.